Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | MAPT | P10636 | 4/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | MYC | P01106 | 1/20 | 0.71 |
| ▸ | MAX | P61244 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6263166 | 1.00 | ALDH1A1 (0.77) | ALDH1A1MAPTGAAMYCMAX | |
| SCHEMBL4058211 | 0.86 | MYC (0.65) | ALDH1A1MAPTGAAMYCMAX | |
| SCHEMBL4057966 | 0.86 | MYC (0.65) | ALDH1A1MAPTGAAMYCMAX | |
| SCHEMBL4058214 | 0.86 | MYC (0.65) | ALDH1A1MAPTGAAMYCMAX | |
| SCHEMBL4057962 | 0.86 | MYC (0.65) | ALDH1A1MAPTGAAMYCMAX | |
| SCHEMBL12961179 | 0.86 | ALDH1A1 (0.75) | ALDH1A1MAPTGAAMYCMAX | |
| SCHEMBL17413661 | 0.86 | MAPT (0.75) | ALDH1A1MAPTGAAMYCMAX | |
| SCHEMBL4048429 | 0.84 | MYC (0.62) | ALDH1A1MAPTGAAMYCMAX | |
| SCHEMBL4048425 | 0.84 | MYC (0.62) | ALDH1A1MAPTGAAMYCMAX | |
| SCHEMBL4049617 | 0.84 | MYC (0.62) | ALDH1A1MAPTGAAMYCMAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005082363-A1 | THIAZOLONE COMPOUNDS FOR TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-09-09 | — | — | WO | claimed |
| US-7872027-B2 | Low molecular weight Myc-max inhibitors | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-01-18 | — | — | US | disclosed |
| US-20070203188-A1 | oncoprotein gene expression inhibitors such as 5-[(4-chlorophenyl)methylidene]-3-(piperidin-1-ylmethyl)-2-sulfanylidene-1,3-thiazolidin-4-one, used as antiproliferative and anticarcinogenic agents | UNIVERSITY OF PITTSBURGH (US) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203188-A1 | oncoprotein gene expression inhibitors such as 5-[(4-chlorophenyl)methylidene]-3-(piperidin-1-ylmethyl)-2-sulfanylidene-1,3-thiazolidin-4-one, used as antiproliferative and anticarcinogenic agents | MYC, MYCBP, MAX | ALDH1A1 3405/4885MAPT 4411/4885GAA 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.